Journal of Advances in Medical and Biomedical Research

en Synergistic effect of colchicine and melatonin in Regulating BAX/BCL2 Expression and Cell Survival in MCF-7 Cell LineCF-7 Cells line Clinical Medicine Clinical Medicine مقاله پژوهشی Original Research Article Background and Objective: Currently, combination drug therapy has emerged as a promising strategy in cancer treatment, as the simultaneous administration of two drugs can enhance therapeutic efficacy and overcome drug resistance. This study aimed to investigate the combined effects of colchicine: microtubule-disrupting alkaloid and melatonin: antioxidant and oncostatic properties on cell viability and expression of apoptosis-related genes (BAX and BCL2) in MCF-7 human breast cancer cell line. Methods: MCF-7 cells were cultured under standard conditions and treated with colchicine, melatonin, or their combination for 24, 48, and 72 hours. Cell viability was determined using MTT assay and BAX and BCL2 gene expression were quantified by reverse transcription polymerase chain reaction. Results: The MTT assay at 48 hours revealed IC50 values of 150 µg/ml for colchicine and 371 µg/ml for melatonin. Combination treatment with colchicine (>25 µg/ml) and a fixed concentration of melatonin (150 µg/ml) resulted in a 50% reduction in cell viability (P<0.01). Gene expression analysis showed that colchicine (75 µg/ml), melatonin (250 µg/ml), and their combination (colchicine: 25 µg/ml; melatonin: 150 µg/ml) significantly increased BAX expression and decreased BCL2 expression compared with the control group (P<0.05). Conclusion: Co-treatment with colchicine and melatonin significantly reduced MCF-7 cell viability and regulated apoptosis-related genes (BAX and BCL2), indicating a synergistic effect. These findings suggest that this combination may represent a promising therapeutic strategy for breast cancer. Further in vivo and clinical studies are required to confirm these findings.   colchicine, melatonin, BAX, BCL2, cell viability, MCF-7 28 28 http://journal.zums.ac.ir/browse.php?a_code=A-10-7384-1&slc_lang=en&sid=1 Fatemeh Yari nastaran.yariii@gmail.com 5200319475328460089039 5200319475328460089039 No Department of clinical biochemistry and genetic, Mazandaran University of Medical Sciences, Sari, Iran. Zynab Sadeghi ghadi sadeghi.g.zaynab@gmail.com 5200319475328460089040 5200319475328460089040 No Department of biotechnology, faculty of advanced technology in medicine, Mazandaran University of medical sciences, sari, Iran Hossien Mahbodi HosseinMahboudi@gmail.com 5200319475328460089041 5200319475328460089041 No Depatment of of Biotechnology, Alborz University of Medical Sciences, Karaj, Iran. Seyed Ehsan Enderami ehsan.enderami@gmail.com 5200319475328460089042 5200319475328460089042 No Department of biotechnology, faculty of advanced technology in medicine, Mazandaran University of medical sciences, sari, Iran Kimia Zargari kim.zar98@gmail.com 5200319475328460089043 5200319475328460089043 No Department of clinical biochemistry and genetic, Mazandaran University of Medical Sciences, Sari, Iran. Mehryar Zargari mzargari@mazums.ac.ir 5200319475328460089044 5200319475328460089044 Yes Professor of Biochemistry, Department of clinical biochemistry and genetic, Molecular and cell biology research center, Faculty of Medicine Mazandaran University of Medical Sciences, Sari, Iran.